Drug Approval | May 08, 2024
USFDA accepts Bristol Myers Squibb’s application for subcutaneous nivolumab
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Aptar Closures’ E-Disc Top securely protects against in-transit leakage while eliminating the need for liners and extra shipping preparation fees
The Unit currently caters to emerging markets of Latin America and Africa with a variety of dosage forms
Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
With this, for all our USFDA facilities, EIRs are in place
ORACEA is a trademark of Galderma Holdings, S.A.
The brand has also unveiled a new TVC campaign in Telangana and Andhra Pradesh to drive brand awareness
The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market
Subscribe To Our Newsletter & Stay Updated
